3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
219
Rectal Neoplasms
137
Stomach Neoplasms
95
Colonic Neoplasms
87
Pancreatic Neoplasms
82
Esophageal Neoplasms
71
Neoplasm Metastasis
58
Squamous Cell Carcinoma of Head and Neck
43
Head and Neck Neoplasms
42
Adenocarcinoma Of Esophagus
37
Neoplasms
36
Breast Neoplasms
35
Esophageal Squamous Cell Carcinoma
27
Carcinoma, Hepatocellular
22
Cholangiocarcinoma
21
Adenocarcinoma
17
Nasopharyngeal Carcinoma
16
Bile Duct Neoplasms
14
Gallbladder Neoplasms
13
Carcinoma, Squamous Cell
13
Biliary Tract Neoplasms
13
Anus Neoplasms
13
Urinary Bladder Neoplasms
11
Liver Neoplasms
10
Carcinoma
9
Nasopharyngeal Neoplasms
8
Colorectal Cancer Metastatic
8
Peritoneal Neoplasms
7
Recurrence
6
Ovarian Neoplasms
6
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Fluorouracil
×
Clear all
NCT02353858
2018-02-13
HT01
University Hospital Tuebingen
Phase 2
Completed
78 enrolled